A Study Of PF-06647263 In Patients With Advanced Solid Tumors
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Neoplasms|Triple-Negative Breast Cancer
Interventions: DRUG: PF-06647263|DRUG: PF-06647263
Sponsor: Pfizer